{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:15Z","timestamp":1786985415171,"version":"build-2736575974"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["2020-2022"],"award-info":[{"award-number":["2020-2022"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.blre.2021.100805","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T18:07:01Z","timestamp":1611252421000},"page":"100805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing"],"prefix":"10.1016","volume":"48","author":[{"given":"Athina","family":"Tampaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Varelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Vlachaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100805_bb0005","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.blre.2021.100805_bb0010","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(04)17192-4","article-title":"Sickle-cell disease","volume":"364","author":"Stuart","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2021.100805_bb0015","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.blre.2021.100805_bb0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3324\/haematol.2016.151159","article-title":"ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease","volume":"102","author":"Kim","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0030","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3324\/haematol.2012.066670","article-title":"Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease","volume":"97","author":"Lamarre","year":"2012","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0035","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100805_bb0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.2019.229989","article-title":"Innate immune cells, major protagonists of sickle cell disease pathophysiology","volume":"105","author":"Allali","year":"2020","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0050","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2021.100805_bb0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy","volume":"95","author":"Roumenina","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100805_bb0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/clin.1994.1072","article-title":"Activation of the alternative complement pathway by red blood cells from patients with sickle cell disease","volume":"71","author":"Chudwin","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2021.100805_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0090-1229(85)90139-4","article-title":"Increased activation of the alternative complement pathway in sickle cell disease","volume":"37","author":"Chudwin","year":"1985","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2021.100805_bb0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/clin.1995.1131","article-title":"Complement activation during painful crisis in sickle cell anemia","volume":"76","author":"Mold","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2021.100805_bb0075","first-page":"130","article-title":"Complement activation in asymptomatic patients with sickle cell anaemia","volume":"36","author":"Wilson","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0080","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2021.100805_bb0085","doi-asserted-by":"crossref","DOI":"10.21767\/2472-5056.100011","article-title":"Typical hus: evidence of acute phase complement activation from a daycare outbreak","volume":"1","author":"Brady","year":"2016","journal-title":"J Clin Exp Nephrol"},{"key":"10.1016\/j.blre.2021.100805_bb0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100805_bb0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2019.03.003","article-title":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: an emerging issue with the introduction of novel treatments","volume":"35","author":"Gavriilaki","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100805_bb0105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1055\/s-0040-1702225","article-title":"Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy","volume":"120","author":"Gavriilaki","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100805_bb0110","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000058","article-title":"Pre- and post-transfusion complement activation in transfusion-dependent beta-thalassaemia","volume":"2","author":"Gavriilaki","year":"2018","journal-title":"Hemasphere."},{"key":"10.1016\/j.blre.2021.100805_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-2776(08)60868-8","article-title":"Control of the complement system","volume":"61","author":"Liszewski","year":"1996","journal-title":"Adv Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.hoc.2015.02.001","article-title":"Complement: an overview for the clinician","volume":"29","author":"Varela","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.blre.2021.100805_bb0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0090-1229(82)90116-7","article-title":"Detection and analysis of inborn and acquired complement abnormalities","volume":"23","author":"Gewurz","year":"1982","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.blre.2021.100805_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0162-3109(99)00007-7","article-title":"Regulation of complement activation by C-reactive protein","volume":"42","author":"Mold","year":"1999","journal-title":"Immunopharmacology."},{"key":"10.1016\/j.blre.2021.100805_bb0140","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/IAI.68.2.688-693.2000","article-title":"Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition","volume":"68","author":"Neth","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.blre.2021.100805_bb0145","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1073\/pnas.1202588109","article-title":"Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2","volume":"109","author":"Heja","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2021.100805_bb0150","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.molimm.2007.11.003","article-title":"The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb)","volume":"45","author":"Bexborn","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0155","first-page":"412","article-title":"Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement","volume":"3","author":"Cortes","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0160","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.blre.2021.100805_bb0165","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.blre.2021.100805_bb0175","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0180","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0185","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe","volume":"102","author":"Maitra","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0195","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"10.1016\/j.blre.2021.100805_bb0205","first-page":"503","article-title":"Alternative pathway activation in sickle cell disease and beta-thalassemia major","volume":"70","author":"deCiutiis","year":"1978","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.blre.2021.100805_bb0210","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJM197304192881601","article-title":"An abnormality of the alternate pathway of complement activation in sickle-cell disease","volume":"288","author":"Johnston","year":"1973","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0215","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V83.3.842.842","article-title":"Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation","volume":"83","author":"Test","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0220","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1172\/JCI111187","article-title":"Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum","volume":"73","author":"Mayes","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0225","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0230","first-page":"77","article-title":"Serum complement activity in normal individuals and patients with sickle cell hemoglobin abnormalities","volume":"33","author":"Francis","year":"1967","journal-title":"Am J Med Technol"},{"key":"10.1016\/j.blre.2021.100805_bb0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.1.6006.367","article-title":"Deficiency of factor B of the complement system in sickle cell anaemia","volume":"1","author":"Wilson","year":"1976","journal-title":"Br Med J"},{"key":"10.1016\/j.blre.2021.100805_bb0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/adc.57.5.343","article-title":"Defective yeast opsonisation and functional deficiency of complement in sickle cell disease","volume":"57","author":"Larcher","year":"1982","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.blre.2021.100805_bb0245","first-page":"56","article-title":"Alternative complement pathway activity in sera from patients with sickle cell disease","volume":"23","author":"Koethe","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1699-0463.1999.tb01463.x","article-title":"Complement haemolytic activity, circulating immune complexes and the morbidity of sickle cell anaemia","volume":"107","author":"Anyaegbu","year":"1999","journal-title":"Apmis."},{"key":"10.1016\/j.blre.2021.100805_bb0255","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI116706","article-title":"Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients","volume":"92","author":"Wang","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0260","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0265","first-page":"248","article-title":"Complement activation in sickle cell disease: a liposome model","volume":"112","author":"Tomasko","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.blre.2021.100805_bb0270","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajh.25384","article-title":"Critical role of C5a in sickle cell disease","volume":"94","author":"Vercellotti","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100805_bb0275","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2021.100805_bb0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/10245332.2016.1231988","article-title":"Expression pattern of CD55 and CD59 on red blood cells in sickle cell disease","volume":"22","author":"Al-Faris","year":"2017","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2021.100805_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2007.06740.x","article-title":"Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability","volume":"139","author":"Ataga","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0290","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/295612a0","article-title":"Release of spectrin-free spicules on reoxygenation of sickled erythrocytes","volume":"295","author":"Allan","year":"1982","journal-title":"Nature."},{"key":"10.1016\/j.blre.2021.100805_bb0295","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/ajh\/hpz116","article-title":"Endothelial microvesicles circulating in peripheral and coronary circulation are associated with central blood pressure in coronary artery disease","volume":"32","author":"Gkaliagkousi","year":"2019","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.blre.2021.100805_bb0300","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1479164119844691","article-title":"Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus","volume":"16","author":"Gkaliagkousi","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.blre.2021.100805_bb0305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/asheducation-2007.1.68","article-title":"Membrane lipid alterations in hemoglobinopathies","volume":"2007","author":"Kuypers","year":"2007","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2021.100805_bb0310","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V87.3.1179.bloodjournal8731179","article-title":"Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V","volume":"87","author":"Kuypers","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0315","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.V88.5.1873.1873","article-title":"Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations","volume":"88","author":"Wood","year":"1996","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1172\/JCI118402","article-title":"Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies","volume":"97","author":"Liu","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0325","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.V98.3.860","article-title":"Characterization of the phosphatidylserine-exposing subpopulation of sickle cells","volume":"98","author":"de Jong","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0330","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.V99.5.1564","article-title":"Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion","volume":"99","author":"Setty","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0335","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1182\/blood.V96.10.3610","article-title":"The survival characteristics of dense sickle cells","volume":"96","author":"Franco","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0340","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1172\/JCI111913","article-title":"Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes","volume":"75","author":"Schwartz","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0345","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07155.x","article-title":"Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy","volume":"142","author":"Westerman","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0350","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.143.5.1663","article-title":"Effect of membrane phospholipids on activation of the alternative complement pathway","volume":"143","author":"Mold","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0355","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0014-5793(86)80350-7","article-title":"Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine","volume":"197","author":"Comis","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/j.blre.2021.100805_bb0360","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","article-title":"The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes","volume":"146","author":"Chonn","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0365","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V32.5.811.811","article-title":"Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases","volume":"32","author":"Muller-Eberhard","year":"1968","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0370","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev.pharmtox.37.1.517","article-title":"The heme oxygenase system: a regulator of second messenger gases","volume":"37","author":"Maines","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.blre.2021.100805_bb0375","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/ars.2009.2787","article-title":"Heme scavenging and the other facets of hemopexin","volume":"12","author":"Tolosano","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.blre.2021.100805_bb0380","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nm1202-799","article-title":"Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease","volume":"8","author":"Reiter","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2021.100805_bb0385","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJM197404112901503","article-title":"Hemopexin metabolism in sickle-cell disease, porphyrias and control subjects--effects of heme injection","volume":"290","author":"Wochner","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0390","doi-asserted-by":"crossref","first-page":"20221","DOI":"10.1074\/jbc.M610737200","article-title":"Characterization of heme as activator of Toll-like receptor 4","volume":"282","author":"Figueiredo","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2021.100805_bb0395","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2014-07-589283","article-title":"Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease","volume":"125","author":"Camus","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1126\/scitranslmed.3001118","article-title":"A central role for free heme in the pathogenesis of severe sepsis","volume":"2","author":"Larsen","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2021.100805_bb0405","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1089\/ars.2007.1787","article-title":"Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment","volume":"9","author":"Balla","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.blre.2021.100805_bb0410","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.4049\/jimmunol.179.8.5543","article-title":"Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria","volume":"179","author":"Pawluczkowycz","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0415","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0420","first-page":"176","article-title":"Effects of extraerythrocytic hemoglobin and its components on mononuclear cell procoagulant activity","volume":"119","author":"Smith","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.blre.2021.100805_bb0425","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3389\/fimmu.2018.03008","article-title":"Heme drives susceptibility of glomerular endothelium to complement overactivation due to inefficient upregulation of heme oxygenase-1","volume":"9","author":"May","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0430","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0435","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3324\/haematol.2012.068965","article-title":"The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe","volume":"98","author":"Nouraie","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0440","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/blood-2012-02-413138","article-title":"Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease","volume":"120","author":"Camus","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0445","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1172\/JCI64578","article-title":"Extracellular hemin crisis triggers acute chest syndrome in sickle mice","volume":"123","author":"Ghosh","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0450","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12445","article-title":"Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease","volume":"162","author":"Adisa","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0455","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1182\/blood-2011-06-361642","article-title":"Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease","volume":"120","author":"Bean","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0460","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1172\/JCI26857","article-title":"Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice","volume":"116","author":"Belcher","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196455","article-title":"Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction","volume":"13","author":"Belcher","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2021.100805_bb0470","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1172\/JCI137282","article-title":"Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes","volume":"130","author":"Pfefferle","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0475","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI117430","article-title":"C5a-induced expression of P-selectin in endothelial cells","volume":"94","author":"Foreman","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2021.100805_bb0480","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0485","doi-asserted-by":"crossref","first-page":"H1608","DOI":"10.1152\/ajpheart.01056.2003","article-title":"Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice","volume":"286","author":"Wood","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.blre.2021.100805_bb0490","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0495","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1179\/102453309X385089","article-title":"Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria","volume":"14","author":"Ruiz-Delgado","year":"2009","journal-title":"Hematology."},{"key":"10.1016\/j.blre.2021.100805_bb0500","doi-asserted-by":"crossref","first-page":"123","DOI":"10.12659\/MSM.889727","article-title":"The presence of CD55- and\/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon","volume":"20","author":"Asimakopoulos","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.blre.2021.100805_bb0505","article-title":"Reduction of CD55 and\/or CD59 in red blood cells of patients with HIV infection","volume":"14","author":"Terpos","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.blre.2021.100805_bb0510","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4049\/jimmunol.1500960","article-title":"TNF regulates essential alternative complement pathway components and impairs activation of protein C in human glomerular endothelial cells","volume":"196","author":"Sartain","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0515","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/09674845.2004.11732650","article-title":"Erythrocyte autoantibodies and expression of CD59 on the surface of red blood cells of polytransfused patients with beta-thalassaemia major","volume":"61","author":"Salama","year":"2004","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.blre.2021.100805_bb0520","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4049\/jimmunol.135.3.2005","article-title":"Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and\/or complement activation","volume":"135","author":"Ross","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0525","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell."},{"key":"10.1016\/j.blre.2021.100805_bb0530","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2015.1.385","article-title":"Complement in hemolytic anemia","volume":"2015","author":"Brodsky","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2021.100805_bb0535","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood.V78.11.3056.3056","article-title":"Characterization of the complement sensitivity of calcium loaded human erythrocytes","volume":"78","author":"Test","year":"1991","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0540","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/ATVBAHA.113.302378","article-title":"Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement","volume":"34","author":"Zecher","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2021.100805_bb0545","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/j.1538-7836.2008.03177.x","article-title":"Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia","volume":"6","author":"Setty","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100805_bb0550","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.trsl.2008.07.007","article-title":"Phosphatidylserine-positive erythrocytes bind to immobilized and soluble thrombospondin-1 via its heparin-binding domain","volume":"152","author":"Gayen Betal","year":"2008","journal-title":"Transl Res"},{"key":"10.1016\/j.blre.2021.100805_bb0555","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood.V98.12.3228","article-title":"Thrombophilia in sickle cell disease: the red cell connection","volume":"98","author":"Setty","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0560","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.V96.3.1119","article-title":"Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation","volume":"96","author":"Setty","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0565","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2003-10-3719","article-title":"Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia\/reoxygenation and inhibited by lovastatin","volume":"104","author":"Solovey","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0570","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2003-03-0693","article-title":"Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes","volume":"102","author":"Shet","year":"2003","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0575","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1365-2141.1998.00627.x","article-title":"Platelet activation in patients with sickle cell disease","volume":"100","author":"Wun","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0580","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood.V99.11.3978","article-title":"Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo","volume":"99","author":"Valles","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0585","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.transci.2016.04.008","article-title":"The role of complement activation in thrombosis and hemolytic anemias","volume":"54","author":"Chapin","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.blre.2021.100805_bb0590","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0595","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2021.100805_bb0600","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2021.100805_bb0605","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.182.6.1807","article-title":"Complement-mediated regulation of tissue factor activity in endothelium","volume":"182","author":"Saadi","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2021.100805_bb0610","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0615","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100805_bb0620","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0625","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0630","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0635","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0640","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2016.153312","article-title":"Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"102","author":"Yuan","year":"2017","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0645","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.blre.2021.100805_bb0650","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.3324\/haematol.2018.194670","article-title":"Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease","volume":"103","author":"Chonat","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0655","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100805_bb0660","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","article-title":"Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement inhibition","volume":"42","author":"Vlachaki","year":"2018","journal-title":"Hemoglobin."},{"key":"10.1016\/j.blre.2021.100805_bb0665","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion."},{"issue":"11","key":"10.1016\/j.blre.2021.100805_bb0670","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3324\/haematol.2020.253856","article-title":"Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease","volume":"105","author":"Floch","year":"2020","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2021.100805_bb0675","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100805_bb0680","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4049\/jimmunol.1900047","article-title":"Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood","volume":"203","author":"Thomas","year":"2019","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.blre.2021.100805_bb0685","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3324\/haematol.2020.262006","article-title":"Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease","volume":"105","author":"Chonat","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2021.100805_bb0690","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bjh.13884","article-title":"Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab","volume":"175","author":"Chonat","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0695","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2021.100805_bb0700","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26566","article-title":"Double trouble: Complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation","volume":"64","author":"Jodele","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.blre.2021.100805_bb0705","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26503","article-title":"Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies","volume":"64","author":"Abusin","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2021.100805_bb0710","article-title":"The first case of COVID-19 treated with the complement C3 inhibitor AMY-101","volume":"108450","author":"Mastaglio","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2021.100805_bb0715","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1111\/bjh.16783","article-title":"Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily","volume":"189","author":"Gavriilaki","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100805_bb0720","doi-asserted-by":"crossref","first-page":"e01753","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.blre.2021.100805_bb0725","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","article-title":"Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV","volume":"7","author":"Jiang","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.blre.2021.100805_bb0730","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:02:41Z","timestamp":1777539761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":146,"alternative-id":["S0268960X21000114"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100805","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100805"}}